Influence of beta-blocker therapy on the risk of infections and death in patients at high risk for stroke induced immunodepression

Ilko L. Maier1*, Johannes C. Becker2*, Johanna Rosemarie Leyhe3, Marlena Schnieder1, Daniel Behme3, Marios-Nikos Psychogios3‡, Jan Liman1‡

1 Department of Neurology, University Medical Center Göttingen, Göttingen, Germany, 2 Department of Neurology, St. Bernward Hospital Hildesheim, Hildesheim, Germany, 3 Department of Neuroradiology, University Medical Center Göttingen, Göttingen, Germany

* These authors contributed equally to this work.
‡ These authors also contributed equally to this work.

ilko.maier@med.uni-goettingen.de

Abstract

Background

Stroke-induced immunodepression is a well characterized complication of acute ischemic stroke. In experimental studies beta-blocker therapy reversed stroke-induced immunodepression, reduced infection rates and mortality. Recent, heterogeneous studies in stroke patients could not provide evidence of a protective effect of beta-blocker therapy. Aim of this study is to investigate the potential preventive effect of beta-blockers in subgroups of patients at high risk for stroke-induced immunodepression.

Methods

Data from a prospectively derived registry of major stroke patients receiving endovascular therapy between 2011–2017 in a tertiary stroke center (University Medical Center Göttingen, Germany) was used. The effect of beta-blocker therapy on pneumonia, urinary tract infection, sepsis and mortality was assessed using multivariate logistic regression analysis.

Results

Three hundred six patients with a mean age of 72 ± 13 years and a median NIHSS of 16 (IQR 10.75–20) were included. 158 patients (51.6%) had pre-stroke-and continued beta-blocker therapy. Beta-blocker therapy did not reduce the incidence of pneumonia (OR 0.78, 95% CI 0.31–1.92, p = 0.584), urinary tract infections (OR 1.51, 0.88–2.60, p = 0.135), sepsis (OR 0.57, 0.18–1.80, p = 0.334) or mortality (OR 0.59, 0.16–2.17, p = 0.429). Strokes involving the insula and anterio-medial cortex increased the risk for pneumonia (OR 4.55, 2.41–8.56, p < 0.001) and sepsis (OR 4.13, 1.81–9.43, p = 0.001), while right hemispheric strokes increased the risk for pneumonia (OR 1.60, 0.92–2.77, p = 0.096). There was a non-significantly increased risk for urinary tract infections in patients with beta-blocker therapy.
and insula/anterio-medial cortex strokes (OR 3.12, 95% CI 0.88–11.05, p = 0.077) with no effect of beta-blocker therapy on pneumonia, sepsis or mortality in both subgroups.

**Conclusions**

In major ischemic stroke patients, beta-blocker therapy did not lower post-stroke infection rates and was associated with urinary tract infections in a subgroup with insula/anterio-medial strokes.

**Introduction**

Infections are frequent and decisive complications after a stroke, as they have a significant influence on stroke outcome [1–3]. Up to a third of all stroke patients subsequently develop infectious complications with pneumonia and urinary tract infections accounting for the majority of cases [4]. As a result of stroke, these patients often show risk factors such as immobilization and dysphagia, which may promote the development of such an infection [5, 6]. However, it has been recognized that stroke patients develop considerably higher rates of infections compared to orthopedic patients with comparable degrees of functional impairments and comorbidities [7]. In this respect, studies have established a link between a damage to the central nervous system and peripheral immunomodulation. Firstly, stroke-associated tissue damage can affect the interaction between the innate and adaptive immune system and hereby impair the specific immune response to bacterial pathogens [8–10]. Secondly, stroke causes the release of stress hormones such as glucocorticoids and catecholamines. These have an immunodepressive effect and influence the functionality of immune cells [9, 11]. The latter finding lead to experimental studies on the effect of beta-antagonists in stroke models.

In an experimental study, Prass et al. found that the administration of propranolol to middle cerebral artery occlusion (MCAO) mice reinforced the immune response and lowered infection rates [11]. Other experimental studies indicated that hepatic invariant natural killer T (INKT)- cells could play an important role in the immunomodulating pathway. In MCAO mice, INKT cells showed an anti-inflammatory phenotype causing higher rates of infections and mortality. The authors were able to reverse this phenotype by the administration of propranolol, which significantly reduced rates of infections and mortality [12].

Previous studies involving humans, however, were inconclusive. Some described a protective effect of beta-blockers regarding infection rates [13–15], others showed a negative effect of beta-blockers with higher rates of adverse events [16].

The main idea behind previous experimental and clinical studies was to antagonize the immunodepressive effects caused by an increase in the sympathetic tone with beta receptor antagonists. This theory has not been sufficiently studied in stroke patients at high risk for infections and in patients likely to exhibit the immunodepressive mechanism previously described in several studies. Our aim was to study the possible immunomodulatory effect of beta-blockers in different subgroups of patients with major ischemic strokes.

**Materials and methods**

**Patient population and clinical characteristics**

Clinical and neuroradiological data were analyzed from a prospectively derived, monocentric database including neuroradiological and neurological information of patients with...
endovascular treatment. The database also included detailed information on pre-stroke medication, past medical history and post-stroke complications. Infection related risk factors like the development of dysphagia, naso-gastric tubes and transurethral catheters were obtained retrospectively through a chart review (IntelliSpace Critical Care and Anesthesia (ICCA) information system (Koninklijke Philips N.V., 2004–2017)), in which detailed information on the clinical course of the stroke patients were documented by stroke physicians and therapists. Ethics approval for this study was sought from the Ethics Committee of the University Medicine Göttingen and all patients or next of kin gave informed written consent for the anonymized use of disease-related data on hospitalization.

All patients were admitted to a neurointensive care unit directly after endovascular treatment and transferred to a stroke unit at various timepoints depending on their clinical status. Patients receiving beta-blockers before the stroke and continued beta-blocker therapy during their in-hospital stay were considered as beta-blocker positive. Patients without beta-blocker exposure before the stroke or during in-patient stay were considered as beta-blocker negative. Patients were included in the analysis, if all necessary data on pre-stroke history (comorbidities and pre-stroke medication)- and clinical data on post stroke course (e.g. infections or complications) were complete and available, which was the case in 306 (59%) from 518 documented cases in the prospectively derived databank.

We defined two high risk subgroups of stroke patients at increased risks for stroke induced immunodepression and post-stroke infections. The first group had insula and antero-medial cortex infarctions, which have been identified to have an increased sympathetic tone and higher risk for post-stroke infections in other studies [17,18]. We assessed the localization of the stroke by using the Alberta Stroke Program Early CT-Score (ASPECTS) [19]. The M1- and M4-regions were defined as antero-medial cortex. The second group with a higher risk for infections were right hemispheric strokes, which in previous studies have been shown to have an increased sympathetic tone [20,21].

**Post-stroke infections**

Following infectious complications were investigated: pneumonia, urinary tract infection and sepsis. For the diagnosis of these infections, the recommendations of the current German guidelines were followed. For the diagnosis of pneumonia, these included a newly diagnosed infiltrate/suspicion of an infiltrate on chest X-ray in presence of at least two clinical signs such as cough, fever (>38.0°C), leukocytosis or leukopaenia (>10,000 or <4,000/l) or the detection of a pneumonia-typical pathogen in the sputum, bronchial secretion or blood [22].

Criteria for the diagnosis of an urinary tract infection included a nitrite-positive urine test strip, bacteria in the midstream urine (10³ colony-forming unit (CFU)/ml with symptoms or 10⁵ CFU/ ml without symptoms) or a positive urine culture with bacteria typical of urinary tract infections [23]. Sepsis was diagnosed, if the sequential (sepsis-related) organ failure assessment (SOFA) score was ≥ 2 in combination with positive blood cultures [24].

**Statistical analysis**

Statistical analysis was performed using SPSS 21 (IBM SPSS Statistics, Armonk, NY, USA). Characteristics of all patients are shown as mean ± standard deviation (SD), if normally distributed, and as median with interquartile range (IQR), if not (Shapiro-Wilk test for normal distribution). Category variables were given as absolute frequencies and percentages and examined by Pearson Chi-Square test for statistically significant differences between the compared groups. The different groups were examined for significant differences by using independent samples T-test or Mann–Whitney U test, as appropriate. Furthermore, to assess the
influence of beta-blocker therapy on post-stroke infections, an uni- and multivariate logistic regression was carried out. Relevant confounders (being predictive for the respective infectious endpoint with a \( p \)-value < 0.2 in an univariate pre-test) were included in a multivariate logistic regression together with the predictor beta-blocker therapy. This logistic regression was performed as an inclusion procedure. In all procedures, a \( p \)-value of < 0.05 was considered as statistically significant.

Results

Baseline characteristics

Patients in the beta-blocker positive group were older (\( p < 0.001 \)), more likely to be female (\( p < 0.001 \)), to have a history of arterial hypertension (\( p < 0.001 \)), coronary heart disease (\( p < 0.001 \)), atrial fibrillation (\( p < 0.001 \)) and chronic renal failure (\( p = 0.006 \), Table 1). There was no significant difference of National Institute of Health Stroke Scale (NIHSS) on admission (median NIHSS 17 vs 15, \( p = 0.068 \)), but patients with beta-blocker therapy had a higher modified Rankin Scale (mRS) on admission (median mRS 5 vs 4, \( p = 0.007 \)) and a higher NIHSS 48 hours after stroke (17 vs 13.5, \( p = 0.014 \)) compared to patients without beta-blocker therapy. Patients in the beta-blocker positive group were more likely to develop dysphagia after the stroke.

Table 1. Baseline characteristics and distribution of potential confounding factors of patients with- and without beta-blocker therapy.

|                  | Beta-Blocker (n = 158) | No-Beta-Blocker (n = 148) | p-value |
|------------------|------------------------|---------------------------|---------|
| Age (mean years ± SD) | 77 (71–83)             | 69 (58–78)                | <0.001  |
| Sex (male, %)     | 58 (36.7)              | 88 (59.5)                 | <0.001  |
| Arterial hypertension (n, %) | 153 (96.8)          | 91 (61.5)                 | <0.001  |
| Hyperlipidemia (n, %) | 73 (48)              | 61 (41.8)                 | 0.296   |
| Diabetes mellitus (n, %) | 53 (34)              | 38 (25.9)                 | 0.134   |
| Atrial fibrillation (n, %) | 89 (57.4)           | 36 (24.7)                 | <0.001  |
| Peripheral arterial disease (n, %) | 13 (8.4)            | 6 (4.1)                   | 0.157   |
| Coronary heart disease (n, %) | 57 (36.5)            | 17 (11.6)                 | <0.001  |
| Chronic renal failure (n, %) | 35 (25)              | 17 (12.1)                 | 0.006   |
| NIHSS admission (median points, IQR) | 17 (11–21)        | 15 (10–19)                | 0.068   |
| NIHSS 48 hours post admission (median points, IQR) | 17 (9–24)          | 13.5 (5–22)               | 0.014   |
| mRS admission (median points, IQR) | 5 (4–5)            | 4 (4–5)                   | 0.007   |
| Successful recanalization (n, %) | 117 (74.5)          | 105 (70.9)                | 0.521   |
| In-hospital days (median, IQR) | 9 (6–18.25)        | 10 (6–19)                 | 0.849   |
| Immunodepressive medication (n, %) | 8 (5.1)             | 17 (11.5)                 | 0.059   |
| Naso-gastric tube (n, %) | 84 (53.2)           | 72 (49)                   | 0.493   |
| Dysphagia (n, %)  | 127 (80.9)            | 99 (66.9)                 | 0.006   |
| Transurethral catheter (n, %) | 149 (94.3)          | 131 (88.5)                | 0.099   |
| Intubation (n, %) | 93 (58.9)             | 100 (67.6)                | 0.124   |
| Length of intubation (median days, IQR) | 1 (1–2)           | 1 (1–3)                   | 0.157   |
| Tracheotomy (n, %) | 11 (7)                | 15 (10.1)                 | 0.413   |
| Time from stroke to tracheotomy (median days, IQR) | 10 (8–19)          | 14 (11–17)                | 0.443   |
| Other intervention (n, %) | 21 (13.3)            | 34 (23)                   | 0.036   |
| Hemicraniection (n, %) | 7 (4.4)              | 18 (12.1)                 | 0.022   |

SD: standard deviation; IQR: interquartile range; Other interventions: non-stroke related major surgical- or invasive diagnostic procedures; Immunodepressive medication: premedication with any drugs that inhibit or prevent activity of the immune system

https://doi.org/10.1371/journal.pone.0196174.t001
stroke (80.9% vs 66.9%, p = 0.006). Rates of decompressive hemicraniectomy and any other interventions (like surgeries or invasive diagnostic procedures) were more frequent in the beta-blocker negative group. Eighty-three patients (52.5%) received bisoprolol, 54 patients (38%) metoprolol, 4 patients (5.1%) nebivolol, 3 patients (2.5%) carvedilol, 2 patients (1.9%) atenolol.

**Effect of beta-blocker therapy on infection rates**

Considering the total patient population, 84 (27.4%) developed pneumonia, 80 (26.1%) an urinary tract infection and 40 (13.1%) sepsis. 64 (20.9%) of the patients died during their in-patient stay.

As shown in Table 2, there was no difference in rates of pneumonia, sepsis and mortality between the beta blocker positive and negative group. Urinary tract infections were more frequently diagnosed in the beta-blocker positive group (50 (31.6%) vs 30 (20.3%) patients, p = 0.027).

Table 3 shows the univariate and multivariate logistic regression of beta-blocker therapy and confounding factors on post-stroke infections and mortality. The univariate analysis showed no effect of beta blocker therapy on pneumonia (OR 1.04, 95% CI 0.63–1.72, p = 0.874), sepsis (OR 1.17, 95% CI 0.65–2.28, p = 0.648) or mortality (OR 1.47, 95% CI 0.84–2.58, p = 0.178). This was also the case for the multivariate logistic regression, which included relevant confounding factors for these infectious endpoints like dysphagia, length of intubation or NIHSS.

Beta blocker therapy was associated with a significantly increased risk for urinary tract infection in the univariate (OR 1.82, 95% CI 1.08–3.07, p = 0.025), but not in the multivariate logistic regression (OR 1.51, 95% CI 0.88–2.60, p = 0.135) analysis.

Patients with- and without beta-blocker therapy showed no difference in leukocyte count, C-reactive protein or procalcitonin concentration (S1 Table).

**Influence of stroke localization**

Patients with strokes affecting the insula and antero-medial cortex showed higher rates of pneumonia (OR 4.55, 95% CI 2.41–8.56, p<0.001), sepsis (OR 4.13, 95% CI 1.81–9.43, p = 0.001) and mortality (OR 13.11, 95% CI 5.41–31.77, p<0.001) compared to patients with other stroke localizations. This stroke localization did not influence the risk for urinary tract infections (OR 1.09, 95% CI 0.59–1.99, p = 0.788).

As shown in Table 4, there was a higher number of patients with an urinary tract infection in the beta-blocker group compared to the non-beta-blocker group (18 (40%) vs 6 (18.8%), p = 0.079) resulting in an increased risk for urinary tract infections in the beta-blocker group (adjusted OR 3.12, 95% CI 0.88–11.05, p = 0.077), which did not reach statistical significance. There was no difference between the beta-blocker positive and beta-blocker negative group for pneumonia, sepsis or mortality in this subgroup.

| Table 2. Infection rates and mortality in patients with- and without beta-blocker therapy. |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Pneumonia (n, %)                              | Beta-Blocker (n = 158)                         | No-Beta-Blocker (n = 148)                     | Overall (n = 306)                             | p-value                                      |
| Pneumonia (n, %)                              | 44 (27.8%)                                    | 40 (27%)                                     | 84 (27.4%)                                   | 0.898                                        |
| Urinary tract infection (n, %)                | 50 (31.6%)                                    | 30 (20.3%)                                   | 80 (26.1%)                                   | 0.027                                        |
| Sepsis (n, %)                                 | 22 (13.9%)                                    | 18 (12.2%)                                   | 40 (13.1%)                                   | 0.735                                        |
| Mortality (n, %)                              | 38 (24.1%)                                    | 26 (17.6%)                                   | 64 (20.9%)                                   | 0.206                                        |

https://doi.org/10.1371/journal.pone.0196174.t002
Table 3. Uni- and multivariate logistic regression models for the association between beta-blocker therapy, post-stroke infections and mortality.

|                  | Univariable analysis | Multivariable analysis |
|------------------|----------------------|------------------------|
|                  | OR (95% CI)          | p-value                |
|                  | OR (95% CI)          | p-value                |
| **Pneumonia**    |                      |                        |
| Beta-blocker     | 1.04 (0.63–1.72)     | 0.874                  |
|                  | 0.78 (0.31–1.92)     | 0.584                  |
| Naso-gastric tube|                      |                        |
|                  |                      |                        |
| NIHSS 48 hours post admission | 2.00 (0.76–5.30) | 0.162                 |
|                  | 0.95 (0.89–1.02)     | 0.144                  |
| Intubation       |                      |                        |
|                  |                      |                        |
| Length of intubation | 0.82 (0.66–1.02) | 0.070                  |
| Tracheotomy      | 0.34 (0.02–7.47)     | 0.490                  |
| Other intervention|                      |                        |
|                  | 3.84 (1.02–14.45)    | 0.046                  |
| Dysphagia        |                      |                        |
|                  | 5.46 (0.54–55.35)    | 0.151                  |
| Age              | 0.99 (0.94–1.03)     | 0.570                  |
| Diabetes mellitus| 2.56 (1.06–6.20)     | 0.037                  |
| Hemicraniection  | 0.59 (0.05–6.99)     | 0.679                  |
| Successful recanalization | 0.88 (0.33–2.38) | 0.814                 |
| mRS admission    | 1.16 (0.70–1.93)     | 0.570                  |
| Insula and antero-medial cortex | 2.45 (0.93–6.45) | 0.069                 |
| Right hemispheric stroke | 1.64 (0.68–3.99) | 0.273                 |
| **Urinary tract infections** |          |                        |
| Beta-blocker     | 1.82 (1.08–3.07)     | 0.025                  |
|                  | 1.51 (0.88–2.60)     | 0.135                  |
| Sex              | 0.54 (0.32–0.94)     | 0.028                  |
| NIHSS admission  | 0.98 (0.94–1.02)     | 0.259                  |
| Transurethral catheter | 1.75 (0.57–5.37) | 0.328                 |
| **Sepsis**       |                      |                        |
| Beta-blocker     | 1.17 (0.65–2.28)     | 0.648                  |
|                  | 0.57 (0.18–1.80)     | 0.334                  |
| Naso-gastric tube| 1.77 (0.52–5.99)     | 0.362                  |
| NIHSS 48 hours post admission | 0.97 (0.89–1.05) | 0.388                 |
| Intubation       | 2.71 (0.51–14.47)    | 0.243                  |
| Length of intubation | 0.79 (0.65–0.98) | 0.031                  |
| Tracheotomy      | 6.71 (0.43–105.41)   | 0.176                  |
| Diabetes mellitus| 1.45 (0.44–4.74)     | 0.542                  |
| Hemicraniection  | 0.07 (0.004–1.37)    | 0.080                  |
| Successful recanalization | 0.88 (0.24–3.24) | 0.850                 |
| mRS admission    | 1.10 (0.61–1.99)     | 0.746                  |
| Insula and antero-medial Cortex | 3.48 (0.93–13.03) | 0.064                 |
| **Mortality**    |                      |                        |
| Beta-blocker     | 1.47 (0.84–2.58)     | 0.178                  |
|                  | 0.59 (0.16–2.17)     | 0.429                  |
| Sepsis           | 3.85 (0.76–19.61)    | 0.104                  |
| Immunosuppressive medication | 1.96 (0.24–16.139) | 0.531                |
| Naso-gastric tube| 0.27 (0.07–1.00)     | 0.050                  |
| Transurethral catheter | 0.02 (0.00–1.56) | 0.080                  |
| Intubation       | 0.78 (0.21–2.87)     | 0.702                  |
| Length of intubation | 0.84 (0.68–1.04) | 0.109                  |
| Tracheotomy      | 0.02 (0.00–0.97)     | 0.048                  |
| Dysphagia        | 12.14 (0.24–611.25)  | 0.212                  |
| Age              | 0.87 (0.80–0.94)     | 0.001                  |
| Diabetes mellitus| 1.14 (0.30–4.319)    | 0.850                  |
| Chronic kidney failure | 1.55 (0.41–5.85) | 0.522                  |

(Continued)
Influence of the side of stroke

There was a non-significant increased risk for pneumonia in patients with right hemispheric strokes (OR 1.60, 95% CI 0.92–2.77, p = 0.096), while there was no influence of right sided strokes on urinary tract infection (OR 0.99, 95% CI 0.57–1.73, p = 0.976) or sepsis (OR 0.98, 95% CI 0.47–2.06, p = 0.963). Right hemispheric strokes were associated with lower mortality (OR 0.57, 95% CI 0.28–1.02, p = 0.057).

In the subgroup of patients with right sided strokes, there was no difference for pneumonia, urinary tract infections, sepsis or mortality between patients with- and without beta-blocker therapy (Table 4).

Discussion

In our study, we found no effect of beta-blocker therapy on rates of post-stroke pneumonia, sepsis or mortality in patients at high risk for stroke induced immunodepression and post-stroke infectious complications, with even increased rates for urinary tract infections. These findings were also true for anatomically defined subgroups with insular/antero-medial cortex and right hemispheric strokes, which have been shown to have increased risks for post-stroke infections and stroke induced immunodepression [17,18].

One general reason for the incapability of beta-blockers to prevent post-stroke immunodepression may be the fact that nowadays mainly cardioselective (beta-1 receptor selective) beta-blockers are used. Previous studies provided evidence, that immune cells may be modulated primarily via beta 2 receptors (rather via beta-1-receptors) by catecholamines [25]. This could

Table 4. Pneumonia, urinary tract infection, sepsis and mortality in patients with insula/antero-medial strokes with- and without beta-blocker therapy.

|                        | Beta-Blocker | No-Beta-Blocker | p-value |
|------------------------|--------------|-----------------|---------|
| **Insula/antero-medial** |              |                 |         |
| strokes (n = 77)        |              |                 |         |
| Pneumonia (n, %)       | 19 (42.2)    | 18 (56.3)       | 0.254   |
| Urinary tract infections (n, %) | 18 (40) | 6 (18.8) | 0.079 |
| Sepsis (n, %)          | 11 (24.4)    | 8 (25)          | 1.000   |
| Mortality (n, %)       | 18 (40)      | 14 (43.8)       | 0.816   |
| **Right hemispheric**  |              |                 |         |
| strokes(n = 113)       |              |                 |         |
| Pneumonia (n, %)       | 17 (32.7)    | 19 (31.1)       | 1.000   |
| Urinary tract infections (n, %) | 17 (32.7) | 12 (19.7) | 0.134 |
| Sepsis (n, %)          | 5 (9.6)      | 9 (14.8)        | 0.569   |
| Mortality (n, %)       | 10 (19.2)    | 6 (10)          | 0.186   |

https://doi.org/10.1371/journal.pone.0196174.t004
be the reason why we could not find protective effects of pre-stroke beta blocker therapy, also
given the fact that previous experimental studies demonstrated a protective effect of unselec-
tive beta-blockers only [11,12]. Two non-experimental studies found a protective effect of
beta-blockers therapy for pneumonia-rates. Dziedzic et al. discussed their findings with a
higher rate of unselective beta-blocker use [13] and Sykora et al. was able to reproduce these
findings with a comparable distribution of beta-blocker types [14]. These studies indicate, that
unselective beta-blockers, as shown in multiple experimental studies, might play a role in
inhibiting stroke induced immunodepressive mechanisms, while beta-1-selective beta blockers
don’t. On the contrary, however, these findings were not confirmed by two recent studies
using prospectively derived data from patients with ischemic- and hemorrhagic stroke receiv-
ing unselective beta-blockers [26, 27]. In conclusion, the role of beta-2-antagonism to prevent
post-stroke infections remains unclear.

A recent subgroup analysis of the Preventive Antibiotics in Stroke Study (PASS)-study also
could not provide evidence for a protective effect of beta blockeer therapy on infections, show-
ing even increased pneumonia-rates [16]. However, the diagnosis of infections in this study
was based on the judgement of the treating physician, the authors did not differentiate between
pre- and continued beta-blocker therapy, did not distinguish between selective- and non-selec-
tive beta-blockers and the NIHSS at baseline was lower compared to our study (5 vs 16 points).
Given these differences, it can be argued that, on the one hand, the pneumonia rates might
have been overestimated and, on the other, the number of patients with stroke-induced immu-
nodepression were lower (due to lower stroke volumes). However, our findings basically
reproduce the findings of the PASS-subanalysis and therefore indicate that there are no differ-
cential effects of beta-blocker therapy in subgroups of minor and major stroke patients.

The increased risk for urinary tract infections associated with beta-blocker therapy could be
explained by the fact, that only major stroke patients were studied, and the diagnosis of urinary
tract infections was primarily based on bacteriological and urinary status in combination with
signs of infections rather than clinical signs attributable to urinary tract infection. These can’t
be judged in the majority of cases in major stroke patients, showing aphasia, confusion and
decreased conscious state. Therefore, rates of urinary tract infection might be overestimated in
our study. The exact mechanism, by which beta-blockers might contribute to an increased rate
of urinary tract infections, remains unclear. Given the pleiotropic and complex effects of beta-
blockade on the immune system on the one-, and sympathetic nervous system and multitude
of organ systems on the other hand, protective effects of beta-blocker therapy might be out-
weighed by detrimental effects of beta-blocker therapy. However, considering the problem of
proper diagnosis and possibility of overestimation of urinary tract infection rates, our study
(together with previous studies reporting increased infection rates) provides safety concerns
for the use of beta-blockers in patient with ischemic stroke.

The strength of the study lies in the fact that we included a homogeneous patient group at
high risk for post-stroke infections and stroke-induced immunodepression, which has not
been studied before. Moreover, we were able to correct for major confounding factors like
naso-gastric tubes, intubation and dysphagia, therefore providing more robust results com-
pared to previous studies [15]. Major limitations of our study include the monocentric design
as well as the lack of included patients with unselective beta-blockers. As detailed pre- and
post-stroke data were incomplete in a significant proportion of patients in the database, selec-
tion bias can’t be ruled out. Lack of statistical power might play a role in the multivariate logis-
tic regression, as multiple confounders have been included. Moreover, the problem of survival
bias should be noted, as very severely affected patients that do not survive the hyperacute
phase after stroke or do receive palliative treatment do not develop post-stroke infections,
which they might have developed if they did survive the hyperacute phase. Another limitation
is that general diagnosis criteria for hospital-acquired pneumonias have been used in this study and not criteria, which specifically have been proposed for the diagnosis of stroke-associated pneumonia by the Pneumonia in Stroke Consensus Group [28].

In conclusion, we could not provide evidence for a protective effect of beta-blockers on post stroke infections and mortality. Data in humans remain inconclusive with studies showing protective effects on pneumonia rates [13, 14] and mortality [29] while other studies show neutral effects [30] or increased rates of infections [16]. The latter may raise safety concerns of these commonly prescribed group of antihypertensive drugs. Our study, however, provides evidence for the safety of beta-blocker therapy concerning the most severe post stroke complications pneumonia, sepsis and death in a major stroke patient group. The increased rate of urinary tract infections in patients with insula/antero-medial strokes associated with beta-blocker therapy, however, should be considered when choosing antihypertensive drugs in major stroke patients at high risk for such infections.

Further studies should investigate the possible effect of unselective beta-blockers on post stroke infections using a prospective design to optimize the control for confounders and should not only identify high risk patients for stroke induced immunodepression using radiological data, but also include serological measurements of catecholamines and cortisol as well as continuous measurements of heart rate and blood pressure to identify an increased sympathetic tone.

Supporting information
S1 Table. Leukocyte count, C-reactive protein and procalcitonin in patients with- and without beta-blocker therapy.
(DOCX)

Acknowledgments
This study was supported by the “Göttinger Kolleg für Translationale Medizin” and the “Niedersächsisches Ministerium für Wissenschaft und Kultur”.

Author Contributions
Conceptualization: Ilko L. Maier, Johannes C. Becker, Jan Liman.
Data curation: Ilko L. Maier, Johannes C. Becker, Marios-Nikos Psychogios.
Formal analysis: Ilko L. Maier, Johannes C. Becker.
Investigation: Ilko L. Maier, Johannes C. Becker, Johanna Rosemarie Leyhe, Marlena Schneider, Daniel Behme, Marios-Nikos Psychogios.
Methodology: Ilko L. Maier, Johanna Rosemarie Leyhe.
Project administration: Ilko L. Maier, Daniel Behme, Marios-Nikos Psychogios.
Software: Ilko L. Maier.
Supervision: Ilko L. Maier, Marios-Nikos Psychogios, Jan Liman.
Validation: Ilko L. Maier.
Visualization: Ilko L. Maier.
Writing – original draft: Ilko L. Maier, Johannes C. Becker.
Writing – review & editing: Johanna Rosemarie Leyhe, Marlena Schnieder, Daniel Behme, Marios-Nikos Psychogios, Jan Liman.

References

1. Heuschmann PU, Kolominsky-Rabas PL, Mielke B, Hermanek P, Leffmann C, Janzen RW, et al. Predictors of In-Hospital Mortality and Attributable Risks of Death After Ischemic Stroke: The German Stroke Registers Study Group. Arch Intern Med. 2004; 164:1761–1768. https://doi.org/10.1001/archinte.164.16.1761 PMID: 15364669

2. Bae HJ, Yoon DS, Lee J, Kim BK, Koo JS, Kwon O, et al. In-Hospital Medical Complications and Long-Term Mortality After Ischemic Stroke. Stroke 2005; 36:2441–2445. https://doi.org/10.1161/01.STR.0000185721.73445.fd PMID: 16224097

3. Koennecke HC, Belz W, Berfelde D, Endres M, Fitzek S, Hamilton F, et al. Factors influencing in-hospital mortality and morbidity in patients treated on a stroke unit. Neurology 2011; 77:965–972. https://doi.org/10.1212/WNL.0b013e31822dc795 PMID: 21865573

4. Westendorp WF, Nederkoorn PJ, Vermeij JD, Dijkgraaf MG, van de Beek D. Post-stroke infection: A systematic review and meta-analysis. BMC Neurol. 2011; 11:110. https://doi.org/10.1186/1471-2377-11-110 PMID: 21933425

5. Martino R, Foley N, Bhogal S, Diamant N, Speechley M, Teasell R, et al. Dysphagia After Stroke Incidence, Diagnosis, and Pulmonary Complications. Stroke 2005; 36:2756–2763. https://doi.org/10.1161/01.STR.0000190056.76543.eb PMID: 16269630

6. Brogan E, Langdon C, Brookes K, Budgeon C, Blacker D. Respiratory infections in acute stroke: nasogastric tubes and immobility are stronger predictors than dysphagia. Dysphagia 2014; 29:340–345. https://doi.org/10.1007/s00455-014-9514-5 PMID: 24445382

7. Lv H, Yin P, Long A, Gao Y, Zhao Z, Li J, et al. Clinical characteristics and risk factors of postoperative pneumonia after hip fracture surgery: a prospective cohort study. Osteoporos. Int. 2016; 27:3001–3009. https://doi.org/10.1007/s00198-016-3624-5 PMID: 27241669

8. Klehmert J, Harms H, Richter M, Prass K, Volk HD, Dimagli U, et al. Stroke-induced immunodepression and post-stroke infections: lessons from the preventive antibacterial therapy in stroke trial. Neurosci-2009; 158:1184–1193. https://doi.org/10.1016/j.neuroscience.2008.07.044 PMID: 18722511

9. Vogelgesang A, May VE, Grunwald U, Barkkeboe M, Langner S, Wallaschofski H, et al. Functional Status of Peripheral Blood T-Cells in Ischemic Stroke Patients. PLoS One. 2010; 5(1):e8718. https://doi.org/10.1371/journal.pone.0008718 PMID: 20090932

10. Hug A, Liesz A, Muerle B, Zhou W, Ehrenheim J, Lorenz A, et al. Reduced Efficacy of Circulating Costimulatory Cells After Focal Cerebral Ischemia. Stroke 2011; 42:3580–3586. https://doi.org/10.1161/STROKEAHA.111.620948 PMID: 21960584

11. Prass K, Meisel C, Höffch C, Braun J, Halle E, Wolf T, et al. Stroke-induced Immunodeficiency Promotes Spontaneous Bacterial Infections and Is Mediated by Sympathetic Activation Reversal by Post-stroke T Helper Cell Type 1–like Immunostimulation. J. Exp. Med. 2003; 198:725–736. https://doi.org/10.1084/jem.20021098 PMID: 12993440

12. Kong CHY, Jenne CN, Lee WY, Léger C, Kubes P. Functional Innervation of Hepatic iNKT Cells Is Immunosuppressive Following Stroke. Science 2011; 334:101–105. https://doi.org/10.1126/science.1210315 PMID: 21921158

13. Dziedzic T, Słowiak A, Pera J, Szczudlik A. Beta-blockers reduce the risk of early death in ischemic stroke. J. Neurol. Sci. 2007; 252:53–56. https://doi.org/10.1016/j.jns.2006.06.007 PMID: 17134722

14. Sykora M, Siarnik P, Diedler J; VISTA Acute Collaborators. β-Blockers, Pneumonia, and Outcome After Ischemic Stroke: Evidence From Virtual International Stroke Trials Archive. Stroke 2015; 46:1269–1274. https://doi.org/10.1161/STROKEAHA.114.008260 PMID: 25899243

15. Maier IL, Karch A, Mikołajczyk R, Bähr M, Liman J. Effect of Beta-Blocker Therapy on the Risk of Infections and Death after Acute Stroke—A Historical Cohort Study. PLoS One. 2015; 10(2):e0116836. https://doi.org/10.1371/journal.pone.0116836 PMID: 25643360

16. Westendorp WF, Vermeij JD, Brouwer MC, Roos YB, Nederkoorn PJ, van de Beek D. Pre-Stroke Use of Beta-Blockers Does Not Lower Post-Stroke Infection Rate: An Exploratory Analysis of the Preventive Antibiotics in Stroke Study. Cerebrovasc. Dis. 2016; 42:506–511. https://doi.org/10.1159/000450926 PMID: 27701710

17. Harms H, Reimnitz P, Bohner G, Werich T, Klingebiel R, Meisel C, et al. Influence of stroke localization on autonomic activation, immunodepression, and post-stroke infection. Cerebrovasc. Dis. 2011; 32:552–560. https://doi.org/10.1159/000331922 PMID: 22104620
18. Walter U, Kolbaske S, Patejdl R, Steinhagen V, Abu-Mugheisib M, Grossmann A, et al. Insular stroke is associated with acute sympathetic hyperactivation and immunodepression. *Eur. J. Neurol.* 2013; 20:153–159. https://doi.org/10.1111/j.1468-1331.2012.03818.x PMID: 22834894

19. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. *The Lancet* 2000; 355:1670–1674.

20. Sander D, Klingelhofer J. Changes of circadian blood pressure patterns and cardiovascular parameters indicate lateralization of sympathetic activation following hemispheric brain infarction. *J. Neurol.* 1995; 242:313–318. PMID: 7643140

21. Meyer S, Strittmatter M, Fischer C, Georg T, Schmitz B. Lateralization in autonomic dysfunction in ischaemic stroke involving the insular cortex. *Neuroreport* 2004; 15:357–361. PMID: 15076768

22. Dalhoff K, Ewig S, Abele-Horn M, Andreas S, Bauer TT, von Baum H, et al. Adult patients with nosocomial pneumonia: epidemiology, diagnosis, and treatment. *Dtsch Arztebl Int.* 2013; 110:634–40. https://doi.org/10.3238/arztebl.2013.0634 PMID: 2413545

23. Choe HS, Lee SJ, Yang SS, Hamasuna R, Yamamoto S, Cho YH, et al. Summary of the UAA-AAUS guidelines for urinary tract infections. *Int J Urol.* 2017

24. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016; 315:801–810. https://doi.org/10.1001/jama.2016.0287 PMID: 26903338

25. Kohm AP, Sanders VM. Norepinephrine and β2-Adrenergic Receptor Stimulation Regulate CD4+ T and B Lymphocyte Function in Vitro and in Vivo. *Pharmacol. Rev.* 2001; 53:487–525. PMID: 11734616

26. Starr JB, Tirschwell DL, Becker KJ. Increased infections with β-blocker use in ischemic stroke, a β2-receptor mediated process? *Neurol Sci.* 2017; 38:967–974. https://doi.org/10.1007/s10072-017-2877-x PMID: 28258316

27. Starr JB, Tirschwell DL, Becker KJ. Labetalol Use Is Associated With Increased In-Hospital Infection Compared With Nicardpine Use in Intracerebral Hemorrhage. *Stroke.* 2017; 48:2693–2698. https://doi.org/10.1161/STROKEAHA.117.017230 PMID: 28904237

28. Smith CJ, Kishore AK, Vail A, Chamorro A, Garau J, Hopkins SJ, et al. Diagnosis of Stroke-Associated Pneumonia: Recommendations From the Pneumonia in Stroke Consensus Group. *Stroke.* 2015; 46:2335–2340. https://doi.org/10.1161/STROKEAHA.115.009617 PMID: 26111886

29. Phelan C, Alaigh V, Fortunato G, Staff I, Sansing L. Effect of β-adrenergic antagonists on in-hospital mortality after ischemic stroke. *J. Stroke Cerebrovasc. Dis. Off. J. Natl. Stroke Assoc.* 2015; 24:1998–2004.

30. De Raedt S, Haentjens P, De Smedt A, Brouns R, Uyttenboogaart M, Luijckx GJ, et al. Pre-stroke use of beta-blockers does not affect ischaemic stroke severity and outcome. *Eur. J. Neurol.* 2012; 19:234–240. https://doi.org/10.1111/j.1468-1331.2011.03475.x PMID: 21777353